drugset / Trial / NCT01013974

A Study of GSK573719 in Healthy Japanese Male Subjects

NCT01013974

Phase 1 Completed 48 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

This is a single centre, randomized, double blind, placebo controlled, single and repeat dose study to investigate the safety, tolerability, and pharmacokinetics of inhaled dose of GSK573719 with lactose and containing magnesium stearate by a novel dry powder device in healthy Japanese male subjects.

Timeline

Start
2009-10-05
Primary completion
2009-12-18
Completion
2009-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Umeclidinium Other / unclassified 250 ug Inhaled
Subject Umeclidinium Other / unclassified 500 ug Inhaled
Subject Umeclidinium Other / unclassified 1000 ug Inhaled